Neoadjuvant therapy plays an increasingly important role in the multidisciplinary management of gastrointestinal cancers.

In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...

The International Liaison Committee on Resuscitation conducts continuous reviews of new, peer-reviewed, published first aid and cardiopulmonary resuscitation science and publishes more comprehensive ...

MIAMI--(BUSINESS WIRE)--$SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical ...

The drug sulthiame reduces the number of breathing pauses and improves sleep quality in patients with obstructive sleep apnea, according to a European clinical study in which the University of ...

The median overall survival was 47.5 months in the combination arm and 37.6 months in the monotherapy arm. Adding chemotherapy to first-line treatment with osimertinib can improve overall survival (OS ...

LOUISVILLE, Ky. (WAVE) - Norton Healthcare has become the first in Kentucky to unveil a new treatment for pancreatic cancer. The treatment is called endoscopic ultrasound-guided radiofrequency ...

First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support ...

LOUISVILLE, Ky. (WDRB) -- Life-changing cancer technology has arrived at Norton Healthcare for patients with pancreatic cancer. Dr. William Evans III, a gastroenterologist with Norton Gastroenterology ...